The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- define the relative bioavailability ratio between compounded rapamycin and generic rapamycin
研究概览
简要总结
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 40 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Receive AgelessRx's standard Rapamycin treatment protocol
- •Opted to complete at least 1 blood draw at their local Quest Lab
排除标准
- •Not approved for current AgelessRx standard Rapamycin treatment
- •History of uncontrolled disease
- •Unable to complete at least 1 blood draw at their local Quest Lab
研究组 & 干预措施
Compounded Rapamycin
Participants in this group were receiving Compounded Rapamycin (dosages include 5, 10, or 15mg) once per week
干预措施: Rapamycin (Drug)
Generic Rapamycin
Participants in this group were receiving Generia Rapamycin (dosages include 2,3,6, or 8mg) once per week
干预措施: Rapamycin (Drug)
结局指标
主要结局
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin
时间窗: 8 months
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
次要结局
未报告次要终点